Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna GTN provision — Product sales returns by Year
GTN provision — Product sales returns ($M) ($M)
Moderna GTN provision — Product sales returns: $28M in FY2025, down 50.0% from a year earlier.
Latest, FY2025
28
Period ended Dec 31, 2025
Change on a year earlier
-50.0%
56 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 2 (Sales Returns Reserve Rollforward).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GTN provision — Product sales returns ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28 | -50.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 56 | -89.9% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 556 | – | Form 10-K (filed 2024-02-23) ↗ |
Cite this data
StockData. (2026). Moderna GTN provision — Product sales returns ($M), annual FY2023–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/gtn-prov-returns
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.